Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

Science 306 (5695): 384-385

Copyright © 2004 by the American Association for the Advancement of Science

DRUG SAFETY:
Withdrawal of Vioxx Casts a Shadow Over COX-2 Inhibitors

Jennifer Couzin

Will other COX-2 inhibitors suffer a fate similar to that of Vioxx, which was recently found to increase the risk of heart attacks and stroke?


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Biomedical and social contributions to sustainability.
I. Wilmut, T. Wongtawan, M. Quigley, and G. Sullivan (2011)
Phil Trans R Soc A 369, 1730-1747
   Abstract »    Full Text »    PDF »
Resolution of Inflammation in Murine Autoimmune Arthritis Is Disrupted by Cyclooxygenase-2 Inhibition and Restored by Prostaglandin E2-Mediated Lipoxin A4 Production.
M. M. Y. Chan and A. R. Moore (2010)
J. Immunol. 184, 6418-6426
   Abstract »    Full Text »    PDF »
Green Tea Protects Rats against Autoimmune Arthritis by Modulating Disease-Related Immune Events.
H. R. Kim, R. Rajaiah, Q.-L. Wu, S. R. Satpute, M. T. Tan, J. E. Simon, B. M. Berman, and K. D. Moudgil (2008)
J. Nutr. 138, 2111-2116
   Abstract »    Full Text »    PDF »
Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
J. S. Borer, H. Pouleur, E. Abadie, F. Follath, J. Wittes, M. A. Pfeffer, B. Pitt, and F. Zannad (2007)
Eur. Heart J. 28, 1904-1909
   Abstract »    Full Text »    PDF »
Thromboxane A2-induced arrhythmias in the anesthetized rabbit.
M. J. Wacker, S. R. Best, L. M. Kosloski, C. J. Stachura, R. L. Smoot, C. B. Porter, and J. A. Orr (2006)
Am J Physiol Heart Circ Physiol 290, H1353-H1361
   Abstract »    Full Text »    PDF »
Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects..
S. I. Mohammed, D. Dhawan, S. Abraham, P. W. Snyder, D. J. Waters, B. A. Craig, M. Lu, L. Wu, R. Zheng, J. Stewart, et al. (2006)
Mol. Cancer Ther. 5, 329-336
   Abstract »    Full Text »    PDF »
Informed consent - a new approach to drug regulation?.
D. J. Nutt (2006)
J Psychopharmacol 20, 3-4
   PDF »
IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?.
A. D. Rodrigues (2005)
Drug Metab. Dispos. 33, 1567-1575
   Abstract »    Full Text »    PDF »
Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs.
E. Fosslien (2005)
Ann. Clin. Lab. Sci. 35, 347-385
   Abstract »    Full Text »    PDF »
The Promise of Prostaglandins: Have They Fulfilled Their Potential as Therapeutic Targets for the Delay of Preterm Birth?.
D. M. Olson (2005)
Reproductive Sciences 12, 466-478
   Abstract »    PDF »
Cyclooxygenase Inhibitor Ketorolac or Mast Cell Stabilizers: Immunologic Challenges in Cancer Therapy.
M. Khatami and J. Mulshine (2005)
Clin. Cancer Res. 11, 1350-1352
   Full Text »    PDF »
Resolution for Sepsis?.
D. W. Gilroy and P. Vallance (2005)
Circulation 111, 2-4
   Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882